RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07669194, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).

    Inclusion criterion 2

  3. Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors.

    Exclusion criterion 1

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.

    Inclusion criterion 4

  5. Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).

    Exclusion criterion 6

  6. Pregnant or breastfeeding women.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07669194, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 years and older at the time of informed consent.
  • Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).
  • Relapsed or refractory disease, having previously received at least two lines of systemic therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Presence of measurable disease.
  • Adequate hematologic, hepatic, and renal function.
  • Willingness to use effective contraception methods during the study and for a specified period after the last dose.
  • Willing and able to provide written informed consent and comply with the study protocol.

Exclusion Criteria:

  • Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors.
  • Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.
  • Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.
  • Active autoimmune diseases requiring systemic immunosuppressive therapy.
  • Clinically significant, severe, or uncontrolled cardiovascular diseases.
  • Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).
  • Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study.
  • Severe gastrointestinal conditions that may significantly affect the absorption of oral medications.
  • Known severe allergic reactions to any of the study drugs or their excipients.
  • Pregnant or breastfeeding women.

Quoted from ClinicalTrials.gov, NCT07669194, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07669194, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07669194